Investigational drug · Phase 2
RC1416
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Moderate to Severe Asthma.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "RC1416"
First trial start
2026
Mar 6, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RC1416", any sponsor or status.
Conditions studied
As listed on its trial records.
- Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Moderate to Severe Asthma
Approved drugs for the same conditions: Asthma · COPD · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "RC1416" as an intervention, largest first.
- Phase II Trial of RC1416 Injection in AsthmaPivotal-lookingRecruiting
Nanjing RegeneCore Biotech Co., Ltd.Industry
NCT07403487 · 195 participants (planned) · Start Mar 10, 2026 · Primary completion Oct 25, 2027
Drug: RC1416; RC1416 Placebo · For: Moderate to Severe Asthma
Sites: Anqing, China; Suzhou, China; Beijing, China · 44 sites in all
- Phase II Study of RC1416 Injection in COPDPivotal-lookingRecruiting
Nanjing RegeneCore Biotech Co., Ltd.Industry
NCT07402551 · 180 participants (planned) · Start Mar 6, 2026 · Primary completion May 31, 2028
Drug: RC1416; RC1416 Placebo · For: Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Sites: Hefei, China; Suzhou, China; Chongqing, China · 46 sites in all
- A Phase I Study of RC1416 InjectionCompleted
Nanjing RegeneCore Biotech Co., Ltd.Industry
NCT06067490 · 48 participants · Start Jun 29, 2023 · Primary completion May 14, 2024
Drug: RC1416(SAD); Placebo(SAD) · For: Healthy Volunteers
Sites: Beijing, China
- A Phase Ib Study of RC1416 InjectionCompleted
Nanjing RegeneCore Biotech Co., Ltd.Industry
NCT06911866 · 40 participants · Start Oct 25, 2024 · Primary completion Sep 25, 2025
Drug: RC1416; RC1416 Placebo · For: Moderate to Severe Asthma
Sites: Beijing, China; Shenzhen, China; Guilin, China · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- 9MW1911Phase 22 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Chronic Obstructive Pulmonary Disease COPD
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.